<div id="readability-page-1"><div><ul> <li>Biogen (NasdaqGS:BIIB) and Stoke Therapeutics reported promising clinical results for zorevunersen in Dravet syndrome, with data highlighting durable seizure reductions and cognitive benefits.</li> <li>The zorevunersen findings were published in The New England Journal of Medicine, supporting its potential as a disease modifying therapy for this rare, severe epilepsy.</li> <li>Biogen released new high dose SPINRAZA data for spinal muscular atrophy, including long term safety and efficacy updates.</li> <li>The company also advanced its next generation SMA candidate, salanersen, into Phase 3 trials across multiple age groups.</li> </ul> <p>For investors tracking Biogen, the latest data points add fresh detail to a company long associated with neurology and rare disease therapies. Zorevunersen strengthens Biogen's presence in genetic epilepsies, while SPINRAZA and salanersen highlight ongoing work in spinal muscular atrophy across a wide patient spectrum.</p> <p>These clinical updates give you more concrete information to assess Biogen's current pipeline mix and risk profile beyond its existing commercial products. As regulatory milestones and further readouts approach, the balance between near term development costs and potential long term revenue sources will likely remain a key focus for market watchers.</p> <p>Stay updated on the most important news stories for Biogen by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Biogen.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/98dc9e23-21e1-4a99-b26e-4caff76c207a/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTAzLTA4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/98dc9e23-21e1-4a99-b26e-4caff76c207a/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTAzLTA4"/><figcaption>NasdaqGS:BIIB Earnings &amp; Revenue Growth as at Mar 2026</figcaption></figure> <p>2 things going right for Biogen that this headline doesn't cover.</p> <p>For Biogen, this cluster of data around zorevunersen and SMA programs reinforces its focus on high unmet need neurology niches where pricing power and durable treatment use can be important drivers. Zorevunersen’s publication in The New England Journal of Medicine, with multi year seizure and cognitive outcomes in Dravet syndrome, gives Biogen leverage in a rare epilepsy market where large players like UCB and Jazz Pharmaceuticals are also active. At the same time, expanding high dose SPINRAZA data and pushing salanersen into Phase 3 keeps Biogen present across the SMA treatment spectrum alongside competitors such as Roche and Novartis.</p> <h3>How This Fits Into The Biogen Narrative</h3> <ul> <li>The progress in SMA and Dravet syndrome aligns with the narrative that Biogen’s late stage pipeline in neurology and rare disease could support more diversified long term earnings beyond multiple sclerosis and Alzheimer’s therapies.</li> <li>The need for continued R&amp;D spend on zorevunersen, high dose SPINRAZA and salanersen underlines the narrative risk that future results still depend heavily on successful new product launches and execution.</li> <li>The Dravet epilepsy opportunity and once yearly SMA dosing concepts are not fully reflected in the focus on Alzheimer’s, lupus and kidney programs, so this news adds extra optionality to the story.</li> </ul> <p>Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Biogen to help decide what it is worth to you.</p> <h3>The Risks and Rewards Investors Should Consider</h3> <ul> <li>⚠️ Biogen still faces execution risk, as future revenue depends on converting late stage neurology assets like zorevunersen and salanersen into approved, widely used products in the face of strong rivals.</li> <li>⚠️ Analysts have flagged at least one risk around large one off items affecting financial results, which can make it harder to interpret short term profitability while the pipeline is being funded.</li> <li>🎁 Successful SMA and Dravet launches would add to Biogen’s rare disease footprint and could help balance pressure on older franchises in multiple sclerosis.</li> <li>🎁 Analysts also highlight rewards such as earnings growth expectations and views that the shares trade below some fair value estimates, which this kind of late stage progress can help underpin if it ultimately converts to approvals.</li> </ul> <h3>What To Watch Going Forward</h3> <p>From here, keep an eye on a few milestones. For SMA, the April 3, 2026 US FDA decision on the high dose SPINRAZA regimen, plus readouts and recruitment progress in the STELLAR and SOLAR Phase 3 salanersen studies, will show how competitive Biogen can stay against other SMA treatments. For Dravet syndrome, investors will want updates on enrollment and timelines for the Phase 3 EMPEROR trial and any further safety signals as more patients receive zorevunersen. How Biogen talks about commercial expectations for these programs at future conferences will help you gauge their potential contribution within the broader neurology portfolio.</p> <p>To ensure you are always in the loop on how the latest news impacts the investment narrative for Biogen, head to the community page for Biogen to never miss an update on the top community narratives.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Biogen might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

STOK

<p>Biogen and Stoke Therapeutics reported positive clinical results for zorevunersen in Dravet syndrome, indicating potential as a disease-modifying therapy. Biogen also shared new data on SPINRAZA for spinal muscular atrophy (SMA) and advanced salanersen into Phase 3 trials. These developments enhance Biogen's position in neurology and rare diseases, with a focus on high unmet needs. Investors should monitor upcoming regulatory milestones and the company's ability to convert late-stage assets into successful products amidst competition. Analysts highlight both risks and potential rewards related to Biogen's evolving pipeline.</p>

Biogen’s Dravet And SMA Advances Add Depth To Long Term Story